As experts in medical imaging and cardiac safety testing for clinical trials, the hard-working people at BioTel Research — formerly of VirtualScopics and Cardiocore — provide the ideal combination of personal service, global reach, scientific expertise, and on-time data delivery.
As a division of BioTelemetry, Inc. (Nasdaq: BEAT), the world’s leading connected health company, we provide expert clinical research services for the advancement of biopharmaceutical development worldwide. Our organization monitors over one million patients and study subjects per year, while supporting approximately 20,000 sites and provisioning 30,000 devices monthly.
While our teams and infrastructure support studies in every corner of the world, we remain steadfast to our core promise of accessibility, reliability, and expertise in clinical trials.
Our industry-leading scientific and operational experts are carefully selected to complement and enhance your team.
We help you solve problems and create solutions. No matter where in the world. No matter what phase of study.
Combination of Philips and BioTelemetry results in a global leader in patient care management solutions for the hospital and the home
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has completed the acquisition of BioTelemetry, Inc. (NASDAQ: BEAT), a leading U.S.-based provider of remote cardiac diagnostics and monitoring. BioTelemetry’s financial results will be consolidated as part of Philips’ Connected Care business segment as of February 9, 2021.
February 9, 2021
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, today announced that it has successfully completed its previously announced tender offer (the “Offer”) to purchase all outstanding shares of BioTelemetry, Inc. (NASDAQ: BEAT), a leading U.S.-based provider of remote cardiac diagnostics and monitoring for USD 72.00 per share […]
Philips to acquire BioTelemetry, Inc. for USD 72.00 per share; implied enterprise value of USD 2.8 billion (approx. EUR 2.3 billion) Acquisition is a strong fit with Philips’ strategy to transform the delivery of healthcare: combination of Philips’ leading patient monitoring position in the hospital with BioTelemetry’s leading cardiac diagnostics and monitoring position outside the […]
December 18, 2020